Premium
Induction of Humoral and Cell‐Mediated Immune Responses by a Novel Adjuvant Derived From HumanAnaphylatoxin C5a
Author(s) -
Morgan Edward L,
Morgan Brandon N,
Sanderson Sam D,
Thoman Marilyn L,
Phillips Joy A
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1066.18
Subject(s) - adjuvant , antigen , humoral immunity , immune system , antibody , immunology , immunity , biology , cellular immunity , t cell , spleen , in vitro , biochemistry
C5a enhances both humoral and cell‐mediated immunity as well as inflammation. We have developed two molecular adjuvant (MA) analogs based on the C‐terminal region of human C5a [EP67: YSFKDMP(MeL)aR and EP54: YSFKDMPLaR] that trigger immunity. When conjugated to either peptide or whole protein antigen, these analogues enhance both humoral and cell‐mediated immunity in vitro and in vivo. The antibody response induced by a MA‐peptide antigen construct differs from that of a conventional adjuvant (CFA) in that the response is mainly IgG2a and IgG2b. Protein antigen conjugated to EP67 induces a high‐titer mix of IgG1, IgG2a, and IgG2b antibodies. In contrast, OVA induces an IgG1 antibody response. In vitro stimulation of spleen cells derived from EP67‐antigen injected mice produced an enhanced T cell proliferation response compared to mice immunized with antigen alone. This work was supported by Grants Ag09948‐09, AG031496, and AI065712